antivascular drug related proteinuria
Conditions
Interventions
experimental group( phase 1) :prescribe canagliflozin100mg qd
experimental group( phase 2):prescribe canagliflozin 100mg qd
experimental group(phase 3):prescribe canagliflozin 100mg qd
control group(phase 3):prescribe ACEI/ARB with standard dose
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients with advanced malignant solid tumors aged 18-75 years; 2) Patients with proteinuria =1g/24 hours (albuminuria grade 2 and above in CTCAE 5) after being treated with anti-angiogenesis drug (including TKI or monoclonal antibody), and did not fall below 1g/24 hours after a 4-week treatment with ARB or ACEI.
Exclusion criteria
Exclusion criteria: 1) Patients with type I diabetes 2) Patients with moderate to severe renal insufficiency (eGFR<45ml/min) or end-stage renal function undergoing dialysis; 3) Patients with severe liver function injury; 4) Patients with recurrent genitourinary infection and polycystic kidney disease; 5) Patients with uncorrected hypovolemia; 6) Patients with uncontrolled hypertension; 7) Patients with severe allergy to the experimental drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24h urine protein; | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR;ACR;PCR;blood pressure;safety; | — |
Countries
China
Contacts
Public ContactHongyan Ying
Peking Union Medical College Hospital
Outcome results
None listed